The new project is expected to help the company in meeting the growing demand for its manufacturing services, which have quadrupled their revenues in the past four years.
The new campus will be built in phases and will include both research manufacturing and commercial manufacturing facilities.
The new facilities built in the first phase will double the company’s current manufacturing capacity and be operational by the fourth quarter of 2015.
Following completion of the entire project, the Campus will triple current capacity and can have more than 1,500 employees, including chemists, production staff, and supporting staff, to seamlessly move new chemical entities from early stage process development through preclinical and clinical deliveries to commercial production.
WuXi PharmaTech chairman and CEO Ge Li said the project marks an important milestone in STA’s mission of building a fully integrated API development and manufacturing platform.
"It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients," Li said.